NCT03510208View on ClinicalTrials.gov

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Malignant Brain NeoplasmMalignant Glioma
Interventions
PROCEDURE

Near-Infrared Fluorescence Imaging

Undergo NIR imaging

BIOLOGICAL

Panitumumab

Given IV

DRUG

Panitumumab-IRDye800

Given IV

DEVICE

POINPOINT-IR9000

"Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table)."

Trial Locations (1)

94304

RECRUITING

Stanford University School of Medicine, Palo Alto

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Stanford University

OTHER